Disclaimer

We’re actively expanding Guideline Genius to cover the full UKMLA content map. Therefore, you may notice some conditions not uploaded yet, or articles that currently focus on diagnosis and management for now.

We are also continuously reviewing and updating existing content to ensure accuracy and alignment with current guidelines. Some earlier articles are undergoing revision as part of this process. Once all content has been fully reviewed, this will be clearly communicated on the platform.

For updates, follow us on Instagram @guidelinegenius.

We welcome any feedback or suggestions via the anonymous feedback box at the bottom of each article and will do our best to respond promptly.

Thank you for your support.
The Guideline Genius Team

Total Live Articles: 381

Fetal Anomaly Screening Programme

NHS England Screening NHS Fetal Anomaly Screening Programme (FASP)

NICE guideline [NG201] Antenatal care. Aug 2021.

Changes were made to the quadruple test:

  • The NHS Fetal Anomaly Screening Programme previously only offered the quadruple test for Down syndrome; a recommendation to include Edwards’ syndrome was approved by the government in December 2025
  • In short, the quadruple test is now used to screen BOTH Down syndrome and Edward’s syndrome

Date: 31/03/26

There are 2 main screening pathways:

  • Combined test and/or quadruple test – for trisomy 21, 18, 13
  • 20-week anomaly scan – for 11 physical conditions
    • Offered 18+0 – 20+6 weeks

Trisomy 21, 18, 13 Screening Pathway

Approach:

  • First, perform screening tests (these test simply gives a result of higher or lower chance)
  • If the screening test result is higher chance → 2nd line tests

Step 1: Screening Tests

There are 2 main screening tests:

Screening test Indications
Combined test (1st line) Most common screening test, used for most patients who follow the routine antenatal care pathway

Performed between 10-14 weeks

Quadruple test Performed between 14-20 weeks

Indicated if the combined test is NOT appropriate:

  • Women attended antenatal care after 14 weeks, or
  • Unable to measure NT (see below for more details)

Interpretation and subsequent actions (based on combined and/or quadruple tests):

  • Lower chance → reassure and no further tests
  • Higher chance → proceed to 2nd line tests

Combined Test Component and Interpretation

The combined test can screen for trisomy 21, 18, 13 (Down, Edward, Patau syndrome)

The combined test involves assessing:

  • Maternal age
  • Biochemical marker – free β-hCG and PAPP-A
  • Nuchal translucency

Trend interpretation:

Condition Nuchal translucency β-hCG PAPP-A
Down syndrome (trisomy 21)* ↑ (≥3.5 mm)
Edwards syndrome (trisomy 18)
Patau syndrome (trisomy 13)

*Most likely to be examined.

Quadruple Test Component and Interpretation

The NHS Fetal Anomaly Screening Programme previously only offered the quadruple test for Down syndrome.

However, a recommendation to include Edwards syndrome was approved by the government in December 2025. [Ref]

The quadruple test only assesses the chance of the baby having trisomy 21 (Down syndrome) and trisomy 21 (Edwards syndrome)

The quadruple test involves assessing 4 biochemical markers:

Condition β-hCG Inhibin-A AFP Unconjugated oestriol
Down syndrome (trisomy 21)
Edward syndrome (trisomy 18) Normal

Step 2:  NIPT or Confirmatory Test

For those with a higher chance result (from the screening test), offer the women a choice of:

  • Non-invasive prenatal testing (NIPT), or
  • Confirmatory tests (invasive prenatal diagnosis)

NIPT (Non-Invasive Prenatal Testing)

Timing ≤ 21+6 weeks (first sample)
Description Maternal blood test to analyse cffDNA that circulates in the maternal circulation
Interpretation and subsequent actions NIPT results are reported as lower chance or higher chance

Subsequent action:

  • Lower chance → return to routine antenatal care
  • Higher chance → offer the choice of 2 options
    • No further testing, or
    • Proceed to confirmatory tests (invasive prenatal diagnosis) – see below

NIPT is still a screening test, it is more sensitive than the combined and quadruple test, but NOT a diagnostic test.

The only diagnostic tests are chorionic villus sampling or amniocentesis for chromosomal or genetic analysis.

Confirmatory Tests (Invasive Prenatal Diagnosis)

There are 2 confirmatory tests that allow prenatal diagnosis of trisomies 21, 18 and 13:

  1. Chorionic villus sampling
  2. Amniocentesis
Test Gestational age* Description
Chorionic villus sampling 11-14 weeks  Ultrasound-guided transabdominal / transcervical procedure to obtain a sample of placental tissue for chromosomal or genetic analysis
Amniocentesis 15-20 weeks Ultrasound-guided extraction of amniotic fluid for chromosomal or genetic analysis

*Gestational age at the time of referral is a key determinant in selecting the appropriate confirmatory test

NHS England: One in 200 women who have a CVS or amniocentesis will miscarry.

20-week Anomaly Screening Pathway

The 20-week screening scan is also known as the anomaly scan:

  • Timing: 18+0 – 20+6 weeks
  • Description: ultrasound scan to screen for 11 physical conditions

If the scan detected / raised suspicion of physical conditions:

  • Refer, and
  • Offer confirmatory testing (chorionic villus sampling or amniocentesis), and
  • Discuss options of continuing pregnancy vs terminating pregnancy

11 Physical Conditions

  • Trisomy 18 and 13 (Edward’s and Patau’s syndrome)
  • 2 neural tube defects (anencephaly and spina bifida)
  • 3 GI defect (cleft lip, gastroschisis, exomphalos)
  • Congenital diaphragmatic hernia
  • Congenital heart disease
  • Bilateral renal agenesis
  • Severe skeletal dysplasia

References


​​​​​​​

Share Your Feedback Below

UK medical guidelines made easy. From guidelines to genius in minutes!

Quick Links

Cookie Policy

Social Media

© 2026 GUIDELINE GENIUS LTD

Be first to accessour QBank

Sign up to receive major guideline updates and early access when we launch.